Progressive Supranuclear Palsy – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of progressive supranuclear palsy (PSP) comprises epidemiological estimates of diagnosed prevalence across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of PSP for each country, as well as annualized case counts projected to the national population.
The diagnosed prevalence of PSP is forecast over a period of 20 years for the major mature pharmaceutical markets.
DRG Epidemiology’s PSP forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PSP over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts the following PSP patient population:
- Diagnosed prevalent cases.
Note: Coverage may vary by country.
Table of contents
- Progressive Supranuclear Palsy - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Diagnosed Prevalence of Progressive Supranuclear Palsy per 100,000 People of All Ages in 2021 and 2041
- Diagnosed Prevalence of Progressive Supranuclear Palsy per 100,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Progressive Supranuclear Palsy over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Progressive Supranuclear Palsy over the Next 20 Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.